Gamma-aminobutyric acid type A receptor alpha 1 subunit (GABRA1) (GABRA1)

The Gamma-aminobutyric acid type A receptor alpha 1 subunit (GABRA1) is a critical component of the most prevalent inhibitory neurotransmitter receptor in the mammalian central nervous system [1]. As a member of the Cys-loop family of ligand-gated ion channels, it typically forms a heteropentameric complex with beta and gamma subunits to create a chloride-selective pore [2]. Activation of this receptor by GABA leads to hyperpolarization of the postsynaptic neuron, thereby reducing neuronal excitability [3]. The alpha 1 subunit is particularly noted for mediating the sedative, hypnotic, and anticonvulsant properties of benzodiazepines and related "Z-drugs" like zolpidem [4]. Mutations in the GABRA1 gene are strongly associated with genetic epilepsies, such as juvenile myoclonic epilepsy and childhood absence epilepsy [5]. Consequently, this receptor is a primary therapeutic target for treating insomnia, anxiety, and seizure disorders, though its modulation is associated with risks of dependence and cognitive side effects [6]. Selective targeting of the alpha 1 subunit is a key strategy in drug development to achieve hypnotic effects while minimizing the muscle-relaxant and anxiolytic effects associated with other alpha subunits [7].

Other names

GABA(A) receptor subunit alpha-1GABRA1Gamma-aminobutyric acid receptor subunit alpha-1ECA4EJMEJM1

Positive allosteric modulation of the GABA-A receptor chloride channel, typically at the benzodiazepine binding site located at the interface of alpha and gamma subunits, which increases the frequency of channel opening in the presence of GABA.